Related references
Note: Only part of the references are listed.GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure
Minsuk Kim et al.
NATURE MEDICINE (2013)
Monotherapy with the once-weekly GLP-1 analogue dulaglutide for 12 weeks in patients with Type 2 diabetes: dose-dependent effects on glycaemic control in a randomized, double-blind, placebo-controlled study
G. Grunberger et al.
DIABETIC MEDICINE (2012)
Cardiovascular Biology of the Incretin System
John R. Ussher et al.
ENDOCRINE REVIEWS (2012)
LY2189265, a long-acting glucagon-like peptide-1 analogue, showed a dose-dependent effect on insulin secretion in healthy subjects
P. Barrington et al.
DIABETES OBESITY & METABOLISM (2011)
The effects of LY2189265, a long-acting glucagon-like peptide-1 analogue, in a randomized, placebo-controlled, double-blind study of overweight/obese patients with type 2 diabetes: the EGO study
G. E. Umpierrez et al.
DIABETES OBESITY & METABOLISM (2011)
A 5-week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long-acting glucagon-like peptide-1 analogue, in patients with type 2 diabetes
P. Barrington et al.
DIABETES OBESITY & METABOLISM (2011)
Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-like peptide-1
Renato O. Crajoinas et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2011)
Effects of Exenatide on Systolic Blood Pressure in Subjects With Type 2 Diabetes
Ted Okerson et al.
AMERICAN JOURNAL OF HYPERTENSION (2010)
Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure
Mads Halbirk et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2010)
Exendin-4 has an anti-hypertensive effect in salt-sensitive mice model
Kunio Hirata et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2009)
Pulse pressure lowering effect of dual blockade with candesartan and lisinopril vs. high-dose ACE inhibition in hypertensive type 2 diabetic subjects: A CALM II study post-hoc analysis
Soren T. Knudsen et al.
AMERICAN JOURNAL OF HYPERTENSION (2008)
General Multistage Gatekeeping Procedures
Alex Dmitrienko et al.
BIOMETRICAL JOURNAL (2008)
Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways
Kiwon Ban et al.
CIRCULATION (2008)
Weight loss and blood pressure control (Pro)
David W. Harsha et al.
HYPERTENSION (2008)
A randomized, double-blind, placebo-controlled study of the effect of sustained-release bupropion on blood pressure in individuals with mild untreated hypertension
Michael E. Thase et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2008)
Glucagon-like peptide 1(GLP-1) in biology and pathology
JJ Meier et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2005)
Glucagon-like peptide-1 relaxes rat conduit arteries via an endothelium-independent mechanism
T Nyström et al.
REGULATORY PEPTIDES (2005)
Effects of intracerebroventricularly injected glucagon-like peptide-1 on cardiovascular parameters; role of central cholinergic system and vasopressin
N Isbil-Buyukcoskun et al.
REGULATORY PEPTIDES (2004)
Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men
JP Gutzwiller et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats
M Yu et al.
JOURNAL OF HYPERTENSION (2003)
Influence of weight reduction on blood pressure - A meta-analysis of randomized controlled trials
JE Neter et al.
HYPERTENSION (2003)
Epidemiology of cardiovascular complications in type 2 diabetes mellitus
JB Meigs
ACTA DIABETOLOGICA (2003)
Share Paper
